NASDAQ:PYPDRepare Therapeutics Stock Price, Forecast & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Repare Therapeutics.

3 brokers have issued 1 year price objectives for Repare Therapeutics' shares. Their forecasts range from $22.00 to $30.00. On average, they expect Repare Therapeutics' share price to reach $25.00 in the next year. This suggests a possible upside of 79.2% from the stock's current price.
View analysts' price targets for Repare Therapeutics.

News articles about PYPD stock have trended neutral on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Repare Therapeutics earned a news impact score of 0.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Repare Therapeutics.

Some companies that are related to Repare Therapeutics include Orthopediatrics (KIDS), Cryolife (CRY), Co-Diagnostics (CODX), Tactile Systems Technology (TCMD), Vapotherm (VAPO), SurModics (SRDX), MiMedx Group (MDXG), Orthofix Medical (OFIX), Intersect ENT (XENT), Invo Bioscience (IVOB), LeMaitre Vascular (LMAT), SI-Bone (SIBN), Antares Pharma (ATRS), Anika Therapeutics (ANIK) and Repro-Med Systems (REPR).
View all competitors.

(PYPD) raised $50 million in an initial public offering on Friday, June 26th 2020. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers.

Repare Therapeutics trades on the NASDAQ under the ticker symbol "PYPD."

Repare Therapeutics' quiet period expired on Wednesday, August 5th. Repare Therapeutics had issued 3,750,000 shares in its initial public offering on June 26th. The total size of the offering was $60,000,000 based on an initial share price of $16.00. During Repare Therapeutics' quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Shares of PYPD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PYPD stock can currently be purchased for approximately $13.95.

Repare Therapeutics has a market capitalization of $237.79 million. Repare Therapeutics employs 57 workers across the globe.

The official website for Repare Therapeutics is www.polypid.com.

Repare Therapeutics' mailing address is 20 HAMAGSHIMIM STREET MATALON CENTER, PETACH TIKVA L3, 49348. The company can be reached via phone at 972-74-719-5700.